RecruitingNot ApplicableNCT06082492

The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

The Beneficial Value of 18F FDG PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients: the NVALT31-PET Study

Sponsor

Radboud University Medical Center

Enrollment

690 participants

Start Date

Mar 19, 2024

Study Type

INTERVENTIONAL

Conditions

Stage III Non-small Cell Lung Cancer

Summary

The primary objective of this study is to compare the 3-year overall survival of stage III NSCLC patients during follow-up surveillance with 18F-Fluorodeoxyglucose Positron Emission Tomography/ Computerized Tomography (18F FDG PET/CT) versus follow-up with conventional CT surveillance. Participants will receive usual care until 3 years of follow-up (control group) with additional whole-body 18F FDG PET/CT scans during follow-up visits at 6 months, 12 months, 18 months, 24 months, and 36 months of follow-up in the intervention group. Other tasks include: * filling in quality of life (QOL) questionnaires at every time point; * participating in an interview evaluating the addition of the 18F FDG PET/CT scans (optional); * collecting blood at the follow-up time points for our secondary endpoint (optional). Researchers will compare the usual care control group with the intervention group to see if the additional 18F FDG PET/CT scans are (cost-)effective.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether using PET/CT scans during follow-up care can improve outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have completed treatment. Currently, standard follow-up uses CT scans — this study tests whether PET/CT (which shows metabolic activity) provides added benefit. **You may be eligible if...** - You have stage III non-small cell lung cancer (confirmed by biopsy) - You have been treated with curative intent and are now in the follow-up phase - You are 18 years or older - You have reasonable overall health (ECOG 0-2) - You are willing to provide signed consent **You may NOT be eligible if...** - Your expected survival is less than 6 months after completing treatment - There is already evidence that your cancer has come back before the study begins - You have any condition that would interfere with the study assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST18F FDG PET/CT

Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

DIAGNOSTIC_TESTCT scan

CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.

Locations(27)

Tergooi MC

Hilversum, Utrecht, Netherlands

Amsterdam UMC

Amsterdam, Netherlands

Antoni van Leeuwenhoek/Nederlands Kanker Instituut

Amsterdam, Netherlands

OLVG

Amsterdam, Netherlands

Gelre Ziekenhuizen

Apeldoorn & Zutphen, Netherlands

Amphia Ziekenhuis

Breda, Netherlands

Deventer Ziekenhuis

Deventer, Netherlands

Ziekenhuis Gelderse Vallei

Ede, Netherlands

Máxima Medisch Centrum

Eindhoven & Veldhoven, Netherlands

Treant

Emmen, Netherlands

Medisch Spectrum Twente

Enschede, Netherlands

Groene Hart Ziekenhuis

Gouda, Netherlands

Martini Ziekenhuis

Groningen, Netherlands

Tjongerschans ziekenhuis

Heerenveen, Netherlands

Dijklander Ziekenhuis

Hoorn, Netherlands

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

Radboudumc

Nijmegen, Netherlands

Bravis Ziekenhuis

Roosendaal, Netherlands

Maasstad ZIekenhuis

Rotterdam, Netherlands

Franciscus Gasthuis & Vlietland

Schiedam, Netherlands

Haaglanden Medisch Centrum

The Hague, Netherlands

HagaZiekenhuis

The Hague, Netherlands

Elisabeth-TweeSteden Ziekenhuis

Tilburg, Netherlands

Diakonessenhuis

Utrecht, Netherlands

UMC Utrecht

Utrecht, Netherlands

St. Antonius Ziekenhuis

Utrecht & Nieuwegein, Netherlands

Streekziekenhuis Koningin Beatrix

Winterswijk, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06082492

Related Trials

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

NCT0610205711 locations

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT0536117410 locations

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

NCT054682421 location